

ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)

	Three Months Ended		Six Months Ended	
	June 30, 2015	June 30, 2014	June 30, 2015	June 30, 2014
Net sales	\$ 2,191	\$ 1,797	\$ 8,051	\$ 7,968
Cost of sales	1,184	1,005	3,382	3,196
Gross profit	1,007	792	4,669	4,772
Operating expenses:				
Sales and marketing	710	852	3,522	3,849
Administration	1,591	2,804	3,612	4,311
Research and development	272	273	480	551
	2,573	3,929	7,614	8,711
Loss from operations	-1,566	-3,137	-2,945	-3,939
Interest income, net	-	(1)	(1)	(3)
Loss before income tax	-1,566	-3,138	-2,946	-3,942
Income tax	-	-	-	-
Net loss	\$ (1,566)	\$ (3,138)	\$ (2,946)	\$ (3,942)
Basic and diluted loss per share:				
Net loss	\$ (0.10)	\$ (0.19)	\$ (0.18)	\$ (0.24)
Weighted average common shares outstanding:				
Basic and diluted	16,020	16,944	15,956	16,709

ProPhase Labs, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)

	June 30, 2015	December 31, 2014
Cash and cash equivalents	\$ 3,761	\$ 2,926
Accounts receivable	\$ 1,245	\$ 5,836
Inventory	\$ 3,705	\$ 3,292
Total current assets	\$ 9,179	\$ 13,458
Total assets	\$ 12,039	\$ 16,057
Total current liabilities	\$ 3,577	\$ 5,241
Other long term obligations	\$ 100	\$ 100
Total stockholders' equity	\$ 8,362	\$ 10,716